GlassScriptPhysician profile
Oliver M Ancheta
NPI 1366400327
$598.22
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $73.40 | 2019 | |
| Amgen INC. | $65.38 | 2019 | |
| Biogen, INC. | $53.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $39.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.28 | 2019 | |
| Amneal Pharmaceuticals LLC | $36.24 | 2019 | |
| Csl Behring | $36.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $31.78 | 2019 | |
| Emd Serono, INC. | $29.07 | 2019 | |
| Lilly USA, LLC | $28.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.93 | 2019 | |
| Allergan, INC. | $17.59 | 2019 | |
| Owp Pharmaceuticals, INC. | $16.95 | 2019 | |
| Acorda Therapeutics, INC | $14.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.21 | 2019 | |
| Strongbridge US INC. | $13.27 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2019 | |
| Genzyme Corporation | $12.05 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Ancheta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.